Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report
| Autor: | Yang Hu, Zhijun Wang, Yanping Hu, Youying Wei, Hui Ren, Jingyi Wu, Caibao Jin, Bin Yang, Yuanxiang Li, Ling Yang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cardiotoxicity
medicine.medical_specialty business.industry medicine.medical_treatment Corticosteroid treatment PD-1/PD-L1 inhibitors Case Report Pembrolizumab Disease Immunotherapy medicine.disease Oncology Internal medicine medicine Pharmacology (medical) Non small cell immune-related cardiotoxicity Adverse effect Lung cancer business non-small cell lung cancer |
| Zdroj: | OncoTargets and therapy |
| ISSN: | 1178-6930 |
| Popis: | PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is relatively rare but may become fatal. We will present a case of a male patient who experienced immunotherapy-related cardiotoxicity one year after received pembrolizumab treatment. The patient had atypical symptom presentation initially, but his condition deteriorated worsened rapidly and he developed severe cardiac disease. The patient experienced significant relief after corticosteroid treatment. Unfortunately, he experienced a reoccurence of the severe adverse event when discontinuing the use of corticosteroids. Ultimately, larger doses and longer courses of corticosteroid treatment cured the heart damage. Fortunately, we observed that lesions were stable and maintained for a long time after cessation of using pembrolizumab for eight months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |